Psychotropic Substances 2026: What Changes for Pharmacies and Laboratories

Key data

Pharmaceutical laboratories, distributors and pharmacies have a new compliance obligation: the Order SND/362/2026, published in the BOE on April 21, 2026, updates annex 1 of Royal Decree 2829/1977 and changes the official classification of psychotropic substances subject to special control in Spain. Any operator that manufactures, distributes, prescribes or dispenses these substances must review its procedures immediately.

This modification responds to Spain's international commitments regarding psychotropic control and strengthens oversight across the entire chain: from the laboratory to the patient.

What does this regulation establish?

Order SND/362/2026 modifies annex 1 of Royal Decree 2829/1977, which is the official catalog of psychotropic substances subject to special control in Spain. This royal decree regulates the processes of manufacturing, distribution, prescription and dispensing of these substances and their medicinal preparations.

The modification involves changes to the official list of controlled substances. The specific details of which substances are added, modified or removed from the annex are contained in the full text published in the BOE, which is the reference source for identifying each affected substance.

The oversight and inspection framework established by Royal Decree 2829/1977 does not disappear: it is maintained in full, but now applies to the new list of substances defined in the updated annex.

Economic and operational impact

The main impact of this order is not economic in terms of new fees or direct costs, but rather operational and regulatory compliance. Affected operators must bear the internal costs of adapting their procedures, records and control systems.

The real economic risks stem from non-compliance:

• Administrative penalties for failing to adapt control and registration procedures to the new classification.
• Criminal liability for sector operators who fail to comply with obligations arising from psychotropic substance regulations.
• Operational shutdowns in case of health inspection if records are not updated in accordance with the new annex.

The cost of adaptation will depend on the size of the operator and the number of affected substances in its catalog or activity. No specific penalty amounts have been published in the available reference text.

Who does it affect?

This regulation affects all operators in the pharmaceutical supply chain that work with psychotropic substances included in annex 1 of Royal Decree 2829/1977:

• Pharmaceutical laboratories: must adapt their manufacturing processes and production records of psychotropic substances to the new classification.
• Distributors: must review their control procedures in the distribution of these substances and update their movement records.
• Pharmacy offices: must verify that their psychotropic substance registration books and dispensing protocols are aligned with the new annex.
• Healthcare professionals who prescribe: must know which substances remain subject to special control following the modification to comply with prescription obligations.

Practical example

A pharmacy that regularly dispenses preparations containing psychotropic substances must, following the publication of Order SND/362/2026, review whether any of the substances it handles has been added or modified in the new annex 1.

If a substance that was not previously subject to special control is now included in the updated annex, that pharmacy will need to incorporate it into its psychotropic substance registration book, apply controlled dispensing protocols and ensure that prescriptions and records comply with oversight requirements. Failure to do so exposes the pharmacy to a health inspection with an unfavorable result and possible administrative penalties.

The same reasoning applies to a laboratory that manufactures a medicinal preparation with any of the affected substances: it will need to review its manufacturing authorization and production records.

What should companies do now?

1. Consult the official text in the BOE: Access the full text of the Order SND/362/2026 to identify exactly which substances have been added, modified or removed from annex 1.
2. Review your own catalog: Cross-reference the substances that your organization manufactures, distributes, prescribes or dispenses with the changes in the new annex to identify which ones are affected.
3. Update control and registration procedures: Adapt registration books, dispensing protocols and internal control systems to the new official classification.
4. Train involved personnel: Ensure that those responsible for manufacturing, distribution, prescription and dispensing are aware of the changes and act in accordance with them.
5. Verify the entry into force date: Confirm in the official text whether the regulation applies from the publication date (April 21, 2026) or if there is an adaptation period, and adjust internal timelines accordingly.
6. Document the adaptation: Keep written records of the reviews conducted and changes implemented, as evidence in case of a health inspection.